Research Should Focus on Grasping Mechanisms of Integrative Kidney Cancer Care

Video

According to an expert from University Hospitals, studying pathways related to inflammation, epigenetics, and the microbiome may elucidate how patients with kidney cancer respond to anti-cancer therapy.

During Kidney Cancer Awareness Month 2023, Santosh Rao, MD, spoke with CancerNetwork® about how future research on mechanisms such as the gut microbiome, inflammation, and epigenetics, may help patients with kidney cancer and other tumors derive more benefit from integrative treatments.

Rao, medical director of integrative oncology for University Hospitals Connor Whole Health and president-elect for the Society for Integrative Oncology, also described the need to broaden the scope of research in terms of integrative medicine by focusing more closely on cancer types beyond breast and prostate cancer, including renal cell carcinoma (RCC), ovarian cancer, and bladder cancer.

Transcript:

First of all, we need to keep doing studies in different types of cancers. While a lot of studies tend to focus on certain types of cancers, we need to broaden it out and have more studies that involve our patients with renal cell carcinoma, bladder cancer, and ovarian cancer. That helps because you don’t want to get the sense that it’s the same for everyone. The more you can engage in studies in different populations or different cancer types, that’s helpful.

The key thing is to have high quality research. If we find that there are things that are beneficial, we need to keep working, in my opinion, on mechanism. There’s this great feeling that a lot of the integrative modalities are partly beneficial just from the placebo effect and getting the sense that we’re just making somebody feel better, which is important in and of itself. But it would be helpful as we learn more to get a better understanding of what’s really happening from a mechanisms standpoint.

Many times, we know that some of the mechanisms are through certain pathways like reducing inflammation and improvements in epigenetics and the microbiome. But getting a better understanding of the interplay between these different systems will give us a better sense of how modifiable different aspects of response to therapy and toxicity. We’re learning more all the time, so I think the science is actually really interesting to me.

Recent Videos
Experts from Vanderbilt University Medical Center discuss the use of intraoperative radiation therapy in a 64-year-old patient with pancreatic cancer.
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Findings show no difference in overall survival between various treatments for metastatic RCC previously managed with immunotherapy and TKIs.
An epigenomic profiling approach may help pick up the entire tumor burden, thereby assisting with detecting sarcomatoid features in those with RCC.
Investigators are assessing the use of IORT in patients with borderline resectable or unresectable pancreatic cancer as part of the phase 2 PACER trial.
The approval for epcoritamab in patients with R/R follicular lymphoma was supported by encouraging efficacy findings from the phase 1/2 EPCORE NHL-1 trial.
A phase 1/2 trial assessed the use of menin inhibitor DSP-5336 in patients with acute leukemia overexpressing HOXA9 and MEIS1.
A phase 1 trial assessed the use of PSCA-directed CAR T cells in patients with metastatic castration-resistant prostate cancer.
A pooled analysis trial assessed the impact of acalabrutinib in patients with chronic lymphocytic leukemia across treatment lines.
Findings from a phase 1 study may inform future trial designs intended to yield longer responses with PSCA-targeted CAR T cells.
Related Content